Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 245 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mineralization Clear all

Conditions: X-linked Hypophosphatemia, Hypophosphatemic Rickets, Hypophosphatemic Rickets, X-Linked Dominant
Interventions: Calcitriol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 3 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Hyperparathyroidism
Interventions: Retrospective Data Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Hip
Interventions: Hip Resurfacing, Total Hip Arthroplasty; Device
Lead sponsor: Spokane Joint Replacement Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Sinus Floor Augmentation, Maxillary Sinus
Interventions: Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation, Anorganic bovine bone mineral in direct sinus augmentation; Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Uterine Cervical Neoplasms
Interventions: Zoledronic acid; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Triumeq; Drug
Lead sponsor: Mills Clinical Research; Industry
Eligibility: 50 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Secondary Osteoporosis, Sarcopenia
Interventions: Exoskeleton-Assisted Walking (EAW) + active Transcutaneous Spinal Cord Stimulation (tSCS), Exoskeleton-assisted walking (EAW) + sham Transcutaneous Spinal Cord Stimulation (tSCS); Device
Lead sponsor: Bronx VA Medical Center; Federal
Eligibility: 21 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Magnesium Deficiency, Calcium Metabolism Disorders
Interventions: vitamin D3; Dietary Supplement
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Transplant
Interventions: Zortress® /Everolimus; Drug
Lead sponsor: University of Kentucky; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Osteoporosis
Interventions: Soy protein; Dietary Supplement
Lead sponsor: Creighton University; Other
Eligibility: 55 Years to 72 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Osteoporosis, Vascular Calcification, Inflammation
Interventions: Vitamin K; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years to 80 Years
Enrollment: 452 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Osteoporosis
Interventions: Placebo, DP001; Drug
Lead sponsor: Deltanoid Pharmaceuticals; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 9
States / cities: Upland, California • Indianapolis, Indiana • Bethesda, Maryland + 6 more

Conditions: Osteoporosis
Interventions: Teriparatide, Alendronate Sodium, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 6
States / cities: Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more

Conditions: Osteoblast, Adipocytes, Bone Density, Osteocalcin, Adiponectin, Mesenchymal Stem Cells
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Osteoporosis
Interventions: Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 15
States / cities: Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more

Conditions: Hyperphosphatemia
Interventions: Niacinamide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bone Mineral Density, Bone Strength
Interventions: LMHF mechanical stimulation active device, LMHF mechanical stimulation placebo device; Device
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 7 Years to 17 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: Increased Dairy Consumption; Other
Lead sponsor: Purdue University; Other
Eligibility: 9 Years to 14 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 2
States / cities: Indianapolis, Indiana • West Lafayette, Indiana

Conditions: Patient Adherence
Interventions: Vitamin D Supplement; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • San Diego, California • Torrance, California

Conditions: Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
Interventions: Etelcalcetide; Drug
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Postmenopausal
Interventions: risedronate, experimental; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 50 Years to 85 Years · Female only
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 4
States / cities: Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more

Conditions: Lactational Amenorrhea, Body Weight Changes, Bone Loss
Interventions: Exercise and dietary; Other
Lead sponsor: North Carolina Agriculture & Technical State University; Other
Eligibility: 25 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Greensboro, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Semaglutide; Drug
Lead sponsor: Emory University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Calcitriol Monotherapy for X-Linked Hypophosphatemia

Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism

Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)

Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study

Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

The Effect of Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation on Bone Strength.

How Does Magnesium Status Influence Calcium Homeostasis?

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

Effect of Soy Isoflavones on Bone Mineral Density and Physical Performance Indices

Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Phase 2 Safety and Efficacy Study of a Vitamin D Compound (DP001) in Postmenopausal Women With Low Bone Mineral Density

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

Effect of Thiazolidinediones on Human Bone

The Forteo Alendronate Comparator Trial

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors

The Effect of Dairy on Bone Mass and Body Composition in 4th-8th Grade Boys and Girls

Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM

The Effect of Etelcalcetide on CKD-MBD

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

Effects of Exercise and Yogurt on Bone Mineral Density and Immunological Factors in Human Milk: The MEEMA Study

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes